What Is the Life Expectancy of a Person With Scleroderma?

Life expectancy with scleroderma varies widely depending on the type, which organs are affected, and how early complications are caught. Many people with milder forms live close to a normal lifespan, while those with the diffuse subtype or serious lung or heart involvement face significantly reduced survival. Across the major subtypes of systemic sclerosis, five-year survival ranges from roughly 85% to 89%, and ten-year survival from about 70% to 82%. Those numbers alone tell you the disease is serious but not uniformly fatal, and the gap between the best and worst outcomes is large enough that individual circumstances matter enormously.

Survival Rates Depend Heavily on Subtype

Systemic sclerosis (the medical name for scleroderma that goes beyond the skin) is not a single disease so much as a spectrum. Researchers typically divide it into three major subtypes: diffuse cutaneous, limited cutaneous, and sine scleroderma (where organ involvement occurs without the classic skin thickening). Each carries a different prognosis.

A large cohort study tracking patients across all three subtypes found clear differences in survival. At five years, about 86% of people with the diffuse form were still alive, compared to roughly 87% with the limited cutaneous form and 89% with sine scleroderma. Those gaps widen over time. At ten years, survival was approximately 70% for diffuse disease, 79% for limited cutaneous, and 82% for sine scleroderma. By fifteen years, just over half of diffuse patients had survived, compared to about 60% with limited cutaneous disease and 82% with sine scleroderma.¹

The diffuse subtype tends to progress faster and involves more widespread skin thickening, and it is more likely to cause early damage to the lungs, heart, and kidneys. Limited cutaneous disease progresses more slowly and primarily affects skin on the hands, forearms, and face. Sine scleroderma, the least common form, is defined by internal organ involvement without the telltale skin changes, and it tends to carry the best long-term outlook of the three.

Lung Disease Is the Biggest Threat

If you asked a scleroderma specialist what they worry about most, the answer would almost certainly be the lungs. Pulmonary involvement is the leading cause of death in systemic sclerosis. It can show up in two main ways: as interstitial lung disease, where scarring gradually stiffens the lung tissue, or as pulmonary arterial hypertension, where blood pressure in the arteries supplying the lungs climbs dangerously high. Some patients develop both at the same time, which compounds the problem.²

Interstitial lung disease often develops in the first few years after diagnosis, particularly in the diffuse subtype. Symptoms can be subtle at first, with shortness of breath during exertion that gradually worsens. Pulmonary arterial hypertension tends to appear later and is more common in the limited cutaneous form. Both conditions are manageable to varying degrees with current treatments, but once either becomes severe, it sharply limits survival. This is why lung function monitoring is a cornerstone of scleroderma care.

The Risk Factors That Predict a Shorter Life

Beyond subtype and lung involvement, researchers have identified several independent factors that predict worse outcomes. A study analyzing predictors of mortality across scleroderma subtypes found four that stood out as statistically significant. Reduced lung diffusing capacity (a measure of how well gas transfers across the lungs), elevated markers of inflammation in the blood, heart involvement, and being male all independently raised the risk of dying.³

The gender difference is striking and consistent across scleroderma research. Men with systemic sclerosis fare worse than women, even after adjusting for other risk factors. Scleroderma is far more common in women, but the men who do develop it tend to present with more aggressive disease, more organ involvement, and higher mortality. The reason is not entirely clear, though differences in immune regulation and the timing of diagnosis likely play a role. Men may also be diagnosed later in the disease course simply because clinicians are less likely to suspect scleroderma in male patients.

Heart involvement is another red flag. Scleroderma can cause fibrosis in the heart muscle itself, inflammation of the lining around the heart, and conduction problems that disrupt the heart’s electrical rhythm. These complications are sometimes silent until they become severe, which is why cardiac screening with echocardiograms and electrocardiograms has become routine in scleroderma management.

How Treatment Has Shifted the Survival Picture

One of the most dramatic improvements in scleroderma survival came not from treating the disease itself, but from managing one of its most dangerous complications. Scleroderma renal crisis, a sudden spike in blood pressure that can cause kidney failure, used to be nearly always fatal. Before a specific class of blood pressure medications became available, only about 15% of patients who developed renal crisis survived a year. After those drugs were introduced, one-year survival jumped to 76%.⁴

That change is worth sitting with. A complication that was once a near-certain death sentence became survivable for the majority of patients, essentially overnight, because of one medication class. Scleroderma renal crisis was historically the leading cause of scleroderma death. With ACE inhibitors keeping it in check, lung disease moved into the top spot, which says less about the lungs getting worse and more about kidneys getting dramatically better.

On the pulmonary side, the picture is more complicated. Several medications can slow or stabilize interstitial lung disease, and treatments for pulmonary arterial hypertension have expanded considerably. The premise behind large patient registries is that catching pulmonary complications early and monitoring them closely can improve outcomes.⁵ The logic is straightforward: if you screen for rising pulmonary pressures or declining lung function and intervene before the damage becomes irreversible, patients live longer. Whether that approach has moved the needle on population-level survival statistics is a more complicated question.

Why Overall Mortality Hasn’t Dropped as Much as You’d Expect

Given the dramatic improvement in managing renal crisis and the availability of newer therapies for lung disease, you might expect scleroderma mortality to have plummeted over the last few decades. It has not, at least not as much as the treatment advances would suggest. A systematic review and meta-analysis looking at mortality trends over forty years found that the standardized mortality ratio for scleroderma patients compared to the general population had not significantly changed.⁶

This sounds discouraging, but the finding needs context. Part of the reason the mortality ratio hasn’t budged is that the general population’s life expectancy has also been climbing, so scleroderma patients need to improve at the same pace just to keep the gap from widening. Another factor is that conquering one cause of death (renal crisis) unmasked the next one (lung disease), which is harder to treat definitively. It is also possible that earlier diagnosis is pulling in patients who previously would have gone undiagnosed or been misclassified, some of whom have severe disease that would have been invisible to older studies.

The practical takeaway is that while individual complications have become more manageable, systemic sclerosis as a whole still carries a meaningfully higher risk of death compared to the general population. Treatment buys time, and sometimes a lot of it, but the disease remains serious.

Localized Scleroderma Is a Different Story

Everything discussed so far applies to systemic sclerosis, the form that affects internal organs. There is another category, localized scleroderma (sometimes called morphea), that primarily involves patches of hardened skin without internal organ damage. Localized scleroderma does not typically affect life expectancy at all. The patches can be cosmetically distressing and occasionally limit joint mobility if they cross a joint, but the disease stays in the skin and underlying tissue.

This distinction matters because “scleroderma” as a term covers both, and someone newly diagnosed with localized morphea may see the survival statistics for systemic sclerosis and be terrified for no reason. If your doctor has told you that you have morphea or localized scleroderma, the survival data in this article does not apply to you. The two conditions share a name and some underlying biology, but they behave very differently.

Age at Diagnosis and How It Shapes Outlook

When systemic sclerosis first appears matters. People diagnosed at a younger age generally have more years of life ahead of them in absolute terms, but the relative impact of the disease can still be significant. Younger patients with diffuse disease may face decades of progressive organ involvement, and the cumulative burden of immunosuppressive treatments brings its own complications, including infection risk and long-term medication side effects.

Older adults diagnosed with scleroderma face a different calculus. Their baseline life expectancy is already shorter, and the additional mortality from scleroderma compresses the timeline further. On the other hand, limited cutaneous disease in a 70-year-old who has no lung involvement and stable skin disease may have only a modest effect on how long that person lives. The disease’s impact on life expectancy is not a fixed number subtracted from everyone’s clock. It depends on what organs are involved, how aggressively the disease behaves in its first few years, and how well complications are managed along the way.

What Routine Monitoring Actually Looks Like

For someone living with systemic sclerosis, the practical side of managing survival risk comes down to regular screening. Lung function tests, typically performed every six to twelve months, track whether interstitial lung disease is developing or progressing. Echocardiograms screen for pulmonary hypertension by estimating pressure in the pulmonary arteries. Blood pressure monitoring catches early signs of renal crisis, which tends to develop suddenly and requires immediate treatment. Blood work tracks inflammation markers and kidney function.

This monitoring regimen is not optional or cosmetic. The evidence consistently shows that complications caught early are more treatable. Pulmonary arterial hypertension that is caught when symptoms are still mild responds better to vasodilator therapy than disease caught after the right side of the heart has already started to fail. Renal crisis caught in the first hours responds better to ACE inhibitors than crisis that has been brewing undetected. The people who do best with scleroderma are generally the ones who stay engaged with their rheumatology team, keep their screening appointments, and report new symptoms early rather than dismissing them.

Pregnancy, Fertility, and Scleroderma

Because scleroderma predominantly affects women, often during their reproductive years, questions about pregnancy come up frequently. Pregnancy in systemic sclerosis is higher risk but not impossible. The main concerns are that pregnancy can sometimes trigger or worsen renal crisis, that certain medications used to manage scleroderma must be stopped before conception because they can harm the fetus, and that reduced lung function may not tolerate the increased cardiovascular demands of pregnancy well.

Women with stable, limited cutaneous disease and no significant organ involvement have successfully carried pregnancies to term. Women with active diffuse disease, significant lung fibrosis, or pulmonary hypertension face substantially higher risks. The timing of pregnancy relative to the disease’s activity is critical. Most scleroderma specialists advise waiting until the disease has been stable for at least a year and coordinating closely with a high-risk obstetrician throughout the pregnancy. Fertility itself is not directly impaired by scleroderma, though some medications used in treatment can affect it temporarily.

Autoimmune Overlap and Misdiagnosis

Scleroderma frequently overlaps with other autoimmune conditions, including lupus, rheumatoid arthritis, and inflammatory myopathy. These overlap syndromes complicate both diagnosis and prognosis. Someone with scleroderma-myositis overlap may face muscle inflammation on top of skin and organ fibrosis, adding another source of disability and risk. Someone with scleroderma-lupus overlap may have kidney involvement driven by lupus nephritis rather than scleroderma renal crisis, which requires a completely different treatment approach.

Misdiagnosis is also a real problem, particularly early in the disease. Raynaud’s phenomenon, where fingers turn white or blue in response to cold, is present in the vast majority of scleroderma patients but is also common in people who never develop scleroderma. Early skin changes can be mistaken for eczema or other dermatologic conditions. Internal organ involvement without skin changes (sine scleroderma) can masquerade as idiopathic pulmonary fibrosis or primary pulmonary hypertension for years before the autoimmune connection is identified. Delays in diagnosis mean delays in screening for the complications that drive mortality, which is why awareness among both patients and general practitioners matters for long-term outcomes.